Navigation Links
Precision Therapeutics' ChemoFx® Demonstrates Significant Role in Selection of Chemotherapy Doublets in Non Small Cell Lung Cancer
Date:4/12/2011

PITTSBURGH, April 12, 2011 /PRNewswire/ -- Drs. Rodney Landreneau and Matthew Schuchert from the University of Pittsburgh presented a new non small cell lung cancer study at the 2011 Society of Surgical Oncology (SSO) conference in San Antonio, Texas.  Dr. Landreneau is Director of the Lung Center at UPMC Shady Side Hospital as well as the Head of Thoracic Surgery at UPMC Passavant Medical Center and Director of the Division of Cardiothoracic Surgery at UPMC St. Margaret Medical Center.  Dr. Matthew J. Schuchert is an Assistant Professor of Surgery in the Department of Cardiothoracic Surgery at the University of Pittsburgh Cancer Institute.  

The study, titled,  "Assessment of In Vitro Chemoresponsiveness to Platinum Based Chemotherapy Doublets Lead to Improvements in 'Individualized' Therapy for Resected Non Small Cell Lung Cancer (NSCLC),"  demonstrates that while 35% of patient specimens evaluated in vitro are resistant to all three standard platinum doublets tested, 28% demonstrate a uniquely variable response, suggesting therefore that ChemoFx® chemoresponse testing may help guide optimal selection of the platinum doublet for treatment, a factor that may be crucial to the patient's outcome.

Christine Gan, Ph.D., a medical science liaison for Precision Therapeutics, noted, "Selecting the optimal platinum doublet for individual NSCLC patients is not straightforward when three equally efficacious options exist.  ChemoFx®, when used as a tool in conjunction with a physician's clinical judgment, can potentially help guide the selection of therapy in this difficult to treat disease."

According to recent statistics, lung cancer is currently responsible for 29% of cancer deaths in the United States, which represents more deaths than breast cancer, colon cancer, and prostate cancer combined. Lung cancer remains the leading cause of cancer deaths for both men and women.

About Precision Therapeutics

Precision Therapeutics, a life-science company based in Pittsburgh, Pennsylvania, is committed to improving outcomes of cancer patients.  As leaders in the science of individualizing cancer therapy through the use of a proprietary and unique live-tissue platform, Precision develops novel markers to help guide treatment decisions based on the biological processes of each individual's cancer.  

Precision's state of the art bioinformatics combined with the analysis of the live molecular, proteomic and genomic activity of each patient's cancer offer an innovative foundation for further development and commercialization of novel predictive markers for cancer therapy. 

ChemoFx® is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician.  Precision currently receives ChemoFx® specimens from 271 top medical institutions including 20 of the 21 National Comprehensive Cancer Network (NCCN) Member Institutions, and 8 of the US News and World Report Top 10 Hospitals for Cancer Care. To date, ChemoFx® Final Reports have been provided for over 56,000 patient specimens, using 105 unique chemotherapy treatments and combinations. For more information, visit www.precisiontherapeutics.com or www.chemofx.com


'/>"/>
SOURCE Precision Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. SACHEM Launches 2-D HPLC e-Learning Program : New e-Learning Program Teaches Scientists How to Better Analyze and Prove Product Purity Through Greater Sensitivity and Precision in Identification of Trace Components
2. Applied Precision Introduces New Super-Resolution Imaging System Doubling Resolution of Traditional Microscopes
3. Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species
4. AMDL, Inc. Signs First Customer Agreement With Precision Diagnostic Laboratory for DR-70 (FDP) Cancer Test
5. Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market
6. NISTs LIDAR may offer peerless precision in remote measurements
7. Precision Stability Storage Announces Upcoming Expansion
8. New statistical technique improves precision of nanotechnology data
9. Precision Therapeutics Named to Inc. Magazines List of Fastest Growing Companies
10. Precision Antibody Wins Contract to Develop Gold Standard Antibodies as Part of National Cancer Institutes Clinical Proteomics Technologies for Cancer (CPTC) Initiative
11. Stretching single molecules allows precision studies of interacting electrons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... Kerafast Inc., developers of an ... across the globe, today announced the availability of a Zika virus antibody from ... treatment and prevention measures for the Zika virus, the virus’s geographical distribution continues ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... and IVF laboratories. A contingency of reproductive endocrinologists, including Dr. George Hill ... experiencing infertility and to help them build families. , Ovation Fertility is a ...
(Date:4/29/2016)... ... ... The MIT bioLogic design team has won multiple A' Design Awards ... applied to fabric and formed into living interfaces between body and environment. They found ... team harvested Natto cells and applied them to fabric with custom 3D printers.The cell-infused ...
(Date:4/29/2016)... ... April 29, 2016 , ... Summit for Stem Cell has received a $250,000 ... patient-specific stem cell therapy for the treatment of Parkinson’s disease. The Summit research project ... The Scripps Research Institute in San Diego, CA. , The aim of ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
Breaking Biology News(10 mins):